Apollo Endosurgery, Inc. (Nasdaq: APEN), a leader in less invasive
medical devices for bariatric and gastrointestinal procedures, today
announced the closing of its previously announced underwritten public
offering of 4,309,090 shares of its common stock, including 562,055
shares sold pursuant to the underwriter’s exercise in full of its option
to purchase additional shares to cover over-allotments. Gross proceeds
from the offering at a public offering price of $5.50 per share, before
underwriting discounts and commissions and offering expenses, were
approximately $23.7 million. All of the common stock was offered and
sold by Apollo.
Craig-Hallum Capital Group acted as the sole managing underwriter for
A shelf registration statement on Form S-3 relating to the offered
shares of common stock was filed with the Securities and Exchange
Commission (the “SEC”), and was declared effective on December 20, 2017.
A prospectus supplement and accompanying prospectus relating to the
offering was filed with the SEC and is available on the SEC’s website,
located at www.sec.gov.
Copies of the final prospectus supplement and accompanying prospectus
related to the offering may be obtained from Craig-Hallum Capital Group
LLC at 222 South Ninth Street, Suite 350, Minneapolis, Minnesota 55402,
Attention: Equity Capital Markets, by telephone at 612-334-6300, or by
e-mail at firstname.lastname@example.org.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy, nor shall there be any sale of these
securities in any state or other jurisdiction in which such an offer,
solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or other
About Apollo Endosurgery, Inc.
Apollo Endosurgery, Inc. is a medical technology company focused on less
invasive therapies for the treatment of obesity, a condition facing over
650 million people globally, as well as other gastrointestinal
conditions. Apollo’s device based therapies are an alternative to
invasive surgical procedures, thus lowering complication rates and
reducing total healthcare costs. Apollo’s products are offered in over
70 countries today and include the OverStitch™ Endoscopic Suturing
System, the ORBERA® Intragastric Balloon, and the LAP-BAND® Adjustable
Gastric Banding System.
Apollo’s common stock is traded on the Nasdaq Global Market under the
View source version on businesswire.com: https://www.businesswire.com/news/home/20180622005033/en/